SCHEMBL2017754

SCHEMBL2017754

CC1(C)CCC(C)(C)c2cc(-c3cccc(N4CCCC(NCCCO)C4)n3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RARB P10826 2/20 0.41
RARA P10276 1/20 0.41
RARG P13631 1/20 0.38
CNR1 P21554 7/20 0.36
PIM1 P11309 5/20 0.36
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
CDC42BPB Q9Y5S2 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.34
KIF18A Q8NI77 1/20 0.34
ASIC3 Q9UHC3 1/20 0.34
PIM2 Q9P1W9 2/20 0.33
PIM3 Q86V86 1/20 0.33
PPARA Q07869 1/20 0.33
AURKA O14965 1/20 0.33
PDPK1 O15530 1/20 0.33
AURKB Q96GD4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12633025 0.97 RARB (0.40) RARBRARARARGCNR1PIM1
SCHEMBL12633026 0.95 RARB (0.42) RARBRARARARGCNR1ASIC3
SCHEMBL2014180 0.93 RARB (0.41) RARBRARARARGCNR1PIM1
SCHEMBL12633028 0.92 RARB (0.41) RARBRARARARGCNR1ASIC3
SCHEMBL2014921 0.90 RARB (0.40) RARBRARARARGCNR1PIM1
SCHEMBL2053040 0.89 RARB (0.43) RARBRARARARGCNR1ASIC3
SCHEMBL2019143 0.87 RARB (0.42) RARBRARARARGCNR1PIM1
SCHEMBL12633915 0.87 RARB (0.41) RARBRARARARGCNR1PIM1
SCHEMBL12959610 0.87 RARB (0.37) RARBRARARARGCNR1PIM1
SCHEMBL2013340 0.86 RARB (0.43) RARBRARARARGCNR1ASIC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 RARB 4194/4885RARA 4373/4885RARG 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.